Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi : bolsters its position on multiple sclerosis with a $765M BTK licensing deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 05:12pm CET

Sanofi is snapping up an early-stage program from San Franciscos Principia Biopharma, shoring up the pharma giants position in multiple sclerosis.

Sanofi will write a check for $40 million upfront, with future milestone payments that could total $765 million. In return, Sanofi gets a worldwide license to develop and sell PRN2246. The asset, which just entered Phase I clinical trials, is a BTK inhibitor designed to access the brain and spinal column by crossing the blood-brain barrier. Once there, its meant to impact immune cell and brain cell signaling. The companies hope this may treat MS and other central nervous system diseases.

The asset makes sense for Sanofi, as the drug maker already has two successful MS drugs on the shelves: Aubagio and Lemtrada. The two products make up a significant part of Sanofis overall revenue.

Sanofis neuroscience research head Rita Balice-Gordon said the investment highlights Sanofis focus on MS and neurological disease.

Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases, Balice-Gordon said.

Principias CEO Martin Babler said partnering with a pharma giant with MS experience allows the startup to make better use of its resources.

The agreement allows Principia to maximize the BTK opportunity in neurology with a strong partner for PRN2246 while focusing internal resources on our lead BTK inhibitor in another therapeutic area, Babler said.

The companys lead program, PRN1008, is in Phase II trials in patients with pemphigus, an orphan autoimmune disease.

The deal between Sanofi and Principia is a tad open-ended. Principia has the option to co-fund Phase III development, should the asset progress that far. If they choose that option, they can get increased royalties on global sales or a profit and loss sharing agreement in the US.

The transaction is expected to close in the fourth quarter.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
11/18 SANOFI : Uptake Strategies and Sanofi win capability development prize at PMEA
11/16 SANOFI : UGA, Sanofi Pasteur develop new broadly protective vaccines for H3N2 in..
11/16 SANOFI : brings innovative medication to Saudi Arabia
11/15 SANOFI : UGA Research Team Explores Impact of Age on Response to Influenza Vacci..
11/15 DR REDDY LABORATORIES : Launches clofarabine generic injection in us
11/14 SANOFI : Principia agree to develop multiple sclerosis drug candidate
11/14 Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/14 IQVIA : Mylan Launches Generic Clolar for Injection
11/14 SANOFI : Experts clarify myths around diabetes
11/13 SANOFI : Body’s inability to manage glucose cause of diabetes not sugar, f..
More news
News from SeekingAlpha
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/15 SANOFI Q3 2017 : Weak Signals
11/15 Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q3 2017 Update
11/14 HEALTHCARE DOGFIGHT : GlaxoSmithKline Regains Top By Gains In November As O&M & ..
11/13 Sanofi Wants To Make A Major Footprint In The Multiple Sclerosis Space
Financials (€)
Sales 2017 35 939 M
EBIT 2017 9 366 M
Net income 2017 7 904 M
Debt 2017 4 659 M
Yield 2017 4,02%
P/E ratio 2017 12,15
P/E ratio 2018 16,16
EV / Sales 2017 2,78x
EV / Sales 2018 2,72x
Capitalization 95 278 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 85,3 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.91%112 309
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550